Effectiveness and safety of dual therapy with co-packaged dolutegravir and lamivudine compared to triple therapy as switching strategy in clinical practice [0.03%]
固定剂量的多替拉韦-拉米夫定与临床实践中切换成三联疗法的疗效和安全性比较研究
Diego Cecchini,Edgardo Bottaro,Brenda Bacelar et al.
Diego Cecchini et al.
Introduction: Dolutegravir plus lamivudine (DTG/3TC) dual therapy has demonstrated efficacy in HIV treatment, but access remains challenging in Latin America. Argentina approved a generic co-packaged DTG+3TC presentation ...
Comparison of Efavirenz and Dolutegravir on Gut Microbiome and Gut Barrier Functions [0.03%]
依非韦伦与多替拉韦对肠道微生物组和肠屏障功能比较研究
Yong-Xiang Huang,Qin Tang,Shi-Hua Fu et al.
Yong-Xiang Huang et al.
Dolutegravir (DTG) is increasingly replacing efavirenz (EFV) as the recommended first-line antiretroviral therapy (cART) component due to its superior tolerance. However, both EFV-based and DTG-based cART regimens are associated with metabo...
Effect of weight gain on blood pressure in Ugandan persons with HIV on dolutegravir/lamivudine/ tenofovir disoproxil fumarate over 48 weeks [0.03%]
乌干达艾滋病患者在接受多替拉韦/拉米夫定/富马酸替诺福韦酯治疗48周内体重增加对血压的影响研究
Willington Amutuhaire,Barbara Castelnuovo,Nele Brusselaers et al.
Willington Amutuhaire et al.
Background: Most people living with HIV in low and middle-income countries are taking fixed dose combination tenofovir disoproxil fumarate/lamivudine/dolutegravir (TLD). Dolutegravir use has been associated with weight ga...
Maintenance therapy with dolutegravir and lamivudine versus bictegravir, emtricitabine, and tenofovir alafenamide in people with HIV (PASO-DOBLE): 48-week results from a randomised, multicentre, open-label, non-inferiority trial [0.03%]
多替拉韦和拉米夫定与比克特拉韦、恩曲他滨和替诺福韦阿拉芬酰胺治疗HIV感染患者的维持疗法：PASO-DOBLE随机、多中心、开放标签非劣效性试验的48周结果
Pablo Ryan,José L Blanco,Mar Masia et al.
Pablo Ryan et al.
Background: Although single-tablet, oral bictegravir, emtricitabine, and tenofovir alafenamide or dolutegravir and lamivudine are preferred regimens in several major guidelines and are widely used in many countries, they ...
HIV-1 drug resistance among people living with HIV receiving dolutegravir-based anti-retroviral regimens in Uganda: a national laboratory-based survey using remnant viral load samples, 2022 [0.03%]
乌干达接受多替拉韦抗逆转录病毒方案的艾滋病毒感染者的HIV-1耐药性：一项使用剩余病毒载量样本的全国实验室基于调查，2022年
Christine Watera,Juliana de Fatima Da Silva,Grace Namayanja et al.
Christine Watera et al.
Background and objectives: Uganda adopted dolutegravir as its preferred HIV treatment regimen in the national guidelines for treatment of HIV and AIDS in 2018. We conducted a survey to estimate dolutegravir resistance 4 y...
Incidence of Metabolic syndrome in people with HIV without experienCe to antiretroviral Therapy who start doLutegravir based-regimen compared with bictegrAvir based-regimeN after 48 weeks (MICTLAN trial) [0.03%]
多替拉韦和比克替拉韦初治HIV感染者治疗48周后代谢综合征发生率的差异：米客特蓝研究
José Antonio Mata Marin,Mara Soraya Rodríguez Evaristo,Ana Luz Cano Díaz et al.
José Antonio Mata Marin et al.
Objective: Evidence suggests that patients initiating a second-generation INSTI-based regimen may have a higher risk of developing metabolic syndrome (MetS) compared to those on other antiretroviral classes. This study ai...
HIV viral suppression after enhanced adherence counselling in children on dolutegravir-based regimens in Malawi [0.03%]
马拉维接受多替拉韦为基础治疗方案的儿童在加强服药依从性咨询后的 HIV 病毒抑制情况
Lucky Makonokaya,Maggie Khumbanyiwa,Louiser U Kalitera et al.
Lucky Makonokaya et al.
Background: Viral suppression (VS) rates in children on antiretroviral therapy (ART) are lower than in adults. We described the effect of enhanced adherence counselling (EAC) on VS among children with high HIV viral load ...
Reduced metformin concentrations in obese women with HIV treated with dolutegravir [0.03%]
接受多替拉韦治疗的肥胖HIV感染女性患者中二甲双胍浓度降低
Roland van Rensburg,Tracy Kellermann,Veshni Pillay-Fuentes Lorente et al.
Roland van Rensburg et al.
Background: Obesity among women with HIV (WWH) is nearly 2-fold higher than in men. Obesity is closely associated with dysglycemia, and frequently necessitates the co-administration of dolutegravir and metformin. A pharma...
Effect of dolutegravir-based antiretroviral therapy on glycemic control in female mice [0.03%]
基于多替拉韦的抗逆转录病毒治疗对雌性小鼠血糖控制的影响
Valeriya Dontsova,Haneesha Mohan,Audrey Yee et al.
Valeriya Dontsova et al.
Dolutegravir (DTG), is recommended for all people with HIV, including pregnant women. Weight gain and hyperglycemia have been reported with DTG use, as well as a signal for neural tube defects (NTDs) that has waned over time. Obesity and hy...
Dolutegravir Derivatives Alleviate LPS-Induced Microglial Inflammation by Suppressing STAT1/3 Nuclear Translocation [0.03%]
多替拉韦衍生物通过抑制STAT1/3核转位缓解LPS诱导的小胶质细胞炎症
Lan Wang,Xiaoting Zhang,Yimian Wang et al.
Lan Wang et al.
Purpose: Microglial inflammation plays a significant role in a variety of neurological disorders. Dolutegravir as a antiretroviral drug has been reported to inhibit the secretion of pro-inflammatory cytokines. Meanwhile, ...
耗时 0.15716 秒，为您在
48229835
条记录里面共找到 1426 篇文章 [XML]